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Background: While prevalence of Hepatitis B virus (HBV) in patients with end-stage re-
nal failure (ESRF) who are undergoing dialysis has decreased significantly during the 
past few decades, it still remains a distinct clinical problem. The immunosuppressive 
nature of renal disease often leads to chronicity of the HBV infection and an opportu-
nity for nosocomial spread of the infection among dialysis patients. Egypt is among the 
countries with intermediate endemicity of HBsAg (range, 2%–7%). Large-scale geographic 
heterogeneity in HBV prevalence has been reported worldwide and HBV prevalence is 
especially heterogeneous in Egypt.
Objectives: To assess the prevalence of occult HBV infection (OBI) in hemodialysis pa-
tients with or without chronic hepatitis C (HCV) from Minia and Assuit, Upper Egypt, 
using HBV DNA assays.
Patient and Methods: Sera from 145 hemodialysis patients with negative HbsAg were in-
vestigated for HBV DNA using real-time polymerase chain reaction (RT-PCR). Only serum 
samples with repeatedly detectable HBV DNA were considered positive. Patients were 
divided into 2 groups: HCV RNA positive and HCV RNA negative, based on the results of 
a third generation enzyme linked immunosorbent assay (ELISA) anti-HCV test and HCV 
RNA PCR. 
Results: HBV DNA was detected in 6 of the 145 patients (4.1%) and HBcAb was detected in 
29/145 patients (20%). There were no statistically significant differences in the age, dura-
tion of hemodialysis, biochemical parameters, serological markers of HBV, or HBV DNA 
between patients with and without HCV infection. 
Conclusions: Four percent of the hemodialysis patients had OBI. There was no signifi-
cant difference in the prevalence of OBI between hemodialysis patients with or without 
HCV co-infection.
  Please cite this paper as: 
Abu El Makarem MA, Abdel Hamid M, Abdel Aleem A, Ali A, Shatat M, Sayed D, et al. Prevalence of Occult Hepatitis B Virus Infection in 
Hemodialysis Patients From Egypt With or Without Hepatitis C Virus Infection. Hepat Mon. 2012;12(4):253-8. DOI: 10.5812/hepatmon.665
 Implication for health policy/practice/research/medical education:
 Exploring  the prevalence of occult HBV infection in hemodialysis patients with or without chronic hepatitis C in Egypt has signifi-
cant clinical implication. Reading this article is recommended to all internists, gastroenterologists and hepatologists.
  c 2012 Kowsar Corp. All rights reserved.
1. Background 
Infections with hepatitis B virus (HBV) and hepatitis 
C virus (HCV) are well-known and important causes of 
liver disease in end-stage renal failure (ESRF) patients on 
hemodialysis (HD) (1-4). Although the prevalence of HBV 254 Hepat Mon. 2012;12(4)
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in patients with ESRF undergoing dialysis has decreased 
significantly during the past few decades (1), it is still a 
distinct clinical problem, as the immunosuppressive na-
ture of renal disease often leads to chronicity of the viral 
infection and results in an opportunity for nosocomial 
spread of the infection among dialysis patients (1-5). Oc-
cult HBV infection (OBI) is defined as the presence of a 
small amount of HBV in patients with serum that tests 
negative for hepatitis B surface antigen (HbsAg). The se-
rum HBV DNA level in these patients is generally lower 
than 104 copies/mL (6). There is a high prevalence of OBI 
in patients with chronic hepatitis C, HCC cryptogenic 
liver disease, and HIV. OBI is also highly prevalent among 
hemodialysis patients, those undergoing frequent blood 
transfusions (as treatment for hemophilia disease, etc.), 
blood donors, and intravenous drug users (7-13).
There is intermediate endemicity of HBsAg in Egypt 
(range, 2%–7%; (14-16). Large-scale geographic heterogene-
ity in HBV prevalence has been reported worldwide, and 
prevalence is especially heterogeneous across Egypt (16). 
Despite the potential clinical importance of OBI, exist-
ing information regarding the prevalence of OBI among 
Egyptian patients undergoing long-term HD is limited. 
2. Objectives
We conducted this study at the 2 main referral centers 
in Upper Egypt (Minia and Assuit) to investigate the prev-
alence of OBI in HD patients. We used a highly sensitive 
and specific PCR method to test for OBI and compared 
OBI prevalence in HCV-positive and HCV negative HD pa-
tients. We also correlated the clinical, epidemiologic, and 
laboratory test characteristics of patients with OBI and 
with or without HCV co-infection. 
3. Patient and Methods
A total of 145 patients with end-stage renal disease 
undergoing regular HD (for at least 6 months) with or 
without HCV RNA positivity by PCR were included in 
this study. Patients were enrolled from 2 of the largest 
nephrology and dialysis units in Upper Egypt (the south-
ern part of Egypt); the dialysis unit of the Department of 
Internal Medicine, Minia University and the dialysis unit 
of the Department of Internal Medicine, Assuit Univer-
sity. We defined chronic HCV infection as the presence 
of anti-HCV antibodies for more than 6 months and 
positive serum HCV RNA (17). We excluded patients with 
acute or chronic HBV infection (as determined by posi-
tive HBsAg), were vaccinated against HBV, other causes of 
liver dysfunction (i.e., primary biliary cirrhosis, autoim-
mune hepatitis, continued alcohol abuse, autoimmune 
hepatitis, and HIV infection), or were being treated with 
interferon and/or ribavirin. We obtained complete medi-
cal history for each patient, including age, location of 
residence, HBV vaccination history, blood transfusion 
history, duration of hemodialysis, etiology of end-stage 
renal disease, and history of schistosomiasis. All patients 
also underwent a complete physical examination. Serum 
samples were collected between May and August 2009 
(before hemodialysis) and then stored at -80C° until 
tested. Serological markers of HBV infection (HBsAg, an-
ti-HBs, anti-HBc, HBeAg, and anti-HBe) were determined 
using standard third generation commercially avail-
able enzyme immunoassays (Abbott GmbH, Wiesbaden-
Delkenheim, Germany).
3.1. Detection of HBV DNA by Polymerase Chain Reaction
Samples from each patient were tested for HBV DNA us-
ing nested PCR (core fragment) techniques, as described 
previously (18). The method uses 4 primers from the X 
region of the HBV genome and has a lower limit of detec-
tion 100 copies/mL. Every sample with HBV DNA detected 
by nested PCR was tested again using a commercially 
available real time PCR kit (COBAS Taqman HBV Test; cut-
off of detection: 6 IU/mL). The COBAS TaqMan HBV Test is 
an in vitro nucleic acid amplification test for quantita-
tion of HBV in human serum or plasma, using the High 
Pure Viral Nucleic Acid kit for manual specimen prepara-
tion and the COBAS TaqMan 48 Analyzer for automated 
amplification and detection. The highly conserved HBV 
precore/core region is amplified for this test. Only serum 
samples with repeatedly detectable HBV DNA were con-
sidered positive for HBV DNA.
3.2. Testing for HCV
Anti-HCV antibody was tested by a third generation en-
zyme-linked immunosorbent assay (ELISA; HCV 3.0 ELISA 
Ortho, Raritan, NJ) according to the manufacturer’s in-
structions. HCV RNA was detected using a qualitative PCR 
assay (COBAS Amplicor HCV Test, v2.0; Roche Diagnostics; 
lower limit of diction; 50 IU/mL). Levels of aspartate ami-
notransferase (AST), alanine aminotransferase (ALT), se-
rum albumin, and bilirubin were determined using stan-
dard techniques. Schistosomal antibodies were assessed 
using an indirect hemagglutination assay with adult 
Schistosoma mansoni worm antigens (Fumouze Laborato-
ries, Levallois-Perret, France) (19). The study protocol was 
approved by the Institutional Ethics Committee at each 
participating center, and all patients gave informed con-
sent prior to participating in this study. The study was 
conducted in accordance with the ethical guidelines of 
the 1975 Declaration of Helsinki and International Con-
ference on Harmonization Guidelines for Good Clinical 
Practice
3.3. Statistical Analysis
Data were analyzed using Sigma Plot software (SPSS, 
version 2). We used Chi-square tests (χ2) to compare quali-
tative variables between groups and Student’s two-tailed 
t-test to compare quantitative variables between groups. 
Data are presented as percentages, means, and standard 255 Hepat Mon. 2012;12(4)
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deviation (SD). P values lower than 0.05 were considered 
significant. 
4. Results 
The baseline demographic characteristics of the pa-
tients are summarized in Table 1. Patients were 47.4 ± 10.4 
years of age (range: 18–69 years), and 82 (56.5%) of the pa-
tients were male. Patients were grouped based on HCV 
PCR status. Group 1 was comprised of 79 patients who 
were HCV RNA-positive. Group 2 consisted of 66 patients 
who were HCV RNA-negative. The mean age of the pa-
tients in groups 1 and 2 was 48.1 ± 10.5 and 46.5 ± 9.8 years, 
respectively. In Group 1, 53.1% of the patients were male, 
while 60.6% of Group 2 patients were male. The mean he-
modialysis duration of groups 1 and 2 were 33.2 ± 11 and 
31.7 ± 10.07 months, respectively. Seventy (88.6%) and 53 
(83.3%) patients in groups 1 and 2, respectively reported 
a history of past blood transfusion (Table 1). We found no 
statistically significant differences between the 2 groups 
based on age, hemodialysis duration or biochemical pa-
rameters, except for serum ALT which was significantly 
higher in group 1 than in group 2 (P = 0.03; Table 1 and 2). 
HBV DNA was detected in 6 of the 145 patients with ESRF 
(4.1%; 95% CI: 2%–6.1%). When these data were stratified 
according HCV RNA positivity; HBV DNA was detected 
through the high-sensitivity PCR study in 4 (5%) and 2 
(3%) of group 1 and group 2 patients, respectively (P = 0.2). 
These 6 patients were considered to have OBI (Table 2). A 
total of 29 (20%) patients tested positive for HBcAb, with 
significantly higher ratio in Group 1 (20 patients (25.3%) 
than in Group 2 patients (29 patients (13.6%)); (P = 0.03) 
(Table 2). There was no significant correlation between 
the presence of HBcAb and age, gender, serum AST, ALT, 
serum albumin, or serum bilirubin. However, in both 
groups there was a significant relationship between HB-
cAb and long duration of hemodialysis, history of blood 
transfusion, and presence of schistosomal antibodies 
(Table 3). The presence of anti-HBc, in the absence of HBV 
DNA, suggests recent recovery from an acute HBV. 
HBV DNA seropositivity was not associated with age, 
sex, history of hepatitis, history of blood transfusion, 
level of schistosomal antibodies, aminotransferase activ-
ity, or serum albumin. As expected, the presence of HBV 
DNA was significantly associated with anti-HBc and anti-
HBe positivity (P = 0.003 and P = 0.002, respectively; Table 
4). While more patients without HBV DNA more patients 
All Patients (n = 145) Group 1 (n = 79) Group 2 (n = 66) P value
Age, y, mean ± SD a 47.4 ± 10.4 48.1 ± 10.5 46.5 ± 9.8 0.3
Sex, No. (%) 0.4
Male 
Female 
82 (56.5)
63 (43.4)
42 (53.1)
37 (46.8)
40 (60.6)
26 (39.3)
Residence, No. (%) 0.4
Rural
Urban
110 (75.8)
35 (24.13)
63 (79.7)
16 (20.2)
48 (72.7)
18 (27.2)
Schistosoma antibodies, No. (%) 0.4
Positive
Negative
87 (60)
58 (40)
51 (64.5)
28 (35.4)
36 (54.5)
30 (45.4)
Duration of hemodialysis, mo, mean ± SD 33.5 ± 10.6 33.2 ± 11 31.7 ± 10.07 0.1
Positive history of transfusion, No. (%) 125 (86.2)/20 (13.7) 70/79 (88.6) 55/66 (83.3) 0.4
AST a, IU/L, mean ± SD 32.7 ± 4.13 32.03 ± 4.28  31.12 ± 2.97 0.1
ALT a, IU/L, mean ± SD 28.63 ± 5.36 29.81 ± 7.28 27.65 ± 3.65 0.03
Albumin, g/dL, mean ± SD 3.4 ± 0.5 3.42 ± 0.4 3.45 ± 0.5 0.4
Bilirubin, mean ± SD  1.9 ± 0.7 1.83 ± 0.6 1.8 ± 0.5 0.1
Table 1. Clinical and Laboratory Characteristics of Hemodialysis Patients Who Were Positive for (Group 1) and Negative for (Group 2) Hepatitis C Virus 
RNA
a Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; SD, standard deviation
All Patients (n = 145) Group 1 (n = 79) Group 2 (n = 66) P value
Anti-HBc b IgG seropositivity 29 (20) 20 (25.3) 9 (13.6) 0.03
Anti-HBs and anti-HBc IgG seropositivity 15 (10.34) 10 (12.6) 5 (7.5) 0.4
Anti-HBc (+), anti-HBe 14 (9.6) 10 (12.6) 4 (6.06) 0.5
HBV DNA c positivity  6 (4.1) 4 (5.06) 2 (3.03) 0.2
Table 2. Prevalence of HBV Serological Markers as Well as HBV DNA in the Study Population a
a Data are Shown as No. (%).
b Abbreviations: Anti-HBc, hepatitis B core antibody. 
c HBV DNA, hepatitis B virus DNA by polymerase chain reaction256 Hepat Mon. 2012;12(4)
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had anti-HBs, the correlation was not statistically signifi-
cant (P = 0.1)
5. Discussion
The present study enrolled HBsAg negative patients, 
regardless their HCV RNA status, and demonstrated that 
4.1% of Egyptian patients with ESRF from Upper Egypt had 
OBI. This prevalence did not differ significantly between 
patients with and without HCV RNA (i.e., 5.06 vs. 3.03 in 
Group 1 and Group 2, respectively). Previous reports from 
studies in dialysis units have indicated that the preva-
lence of OBI ranges from 0% to 58% among patients (2, 
20-22). This wide range of estimates may attributable to 
differences in the sensitivity of the methods used for the 
detection of HBV DNA (23), the patients’ sample investi-
gated in each study, and the level of HBV endemicity in 
the populations of the different geographic areas. The 
most accurate method for OBI testing is the analysis of 
liver DNA extracts and the detection of HBV DNA in se-
rum samples may underestimates the true prevalence of 
OBI (24, 25). However, the performance of liver biopsies 
in patients undergoing HD is often very difficult, and is 
usually contraindicated. A similar prevalence of markers 
of anti-HBc and HBV DNA has recently been found among 
Egyptian blood donations (26).
In this study, HBV DNA seropositivity was not associ-
ated with age, sex, history of hepatitis, history of blood 
transfusions, levels of schistosomal antibodies, amino-
transferase activity, or serum albumin. However, there 
were significant associations between the presence of 
HBV DNA and anti-HBc positivity, and between HBV DNA 
and anti-HBe positivity. The absence of HBV DNA was as-
sociated with the presence of anti-HBs. The prevalence of 
anti-HBc was 20%. As anti-HBc positivity indicates previ-
ous exposure to HBV infection, this finding in our HD pa-
tients in association with negative HBsAg might suggest 
contact with HBV sometime during adulthood. However, 
this cannot be safely assumed for HD patients. Although 
anti-HBc levels were higher in Group 1 (21.9%) than in 
Group 2 (11.5%), this difference was not statistically sig-
nificant. This ratios are in consistent with the available 
data in the literature (2, 21, 27, 28). 
OBI may have an impact in different clinical contexts, 
including possible transmission of the infection (24, 25), 
risk of reactivation (24, 25), contribution to liver disease 
progression (29), and development of hepatocellular 
carcinoma (30). Clinical interactions between HCV and 
OBI are still controversial. Studies performed in differ-
ent geographic areas have shown a significant associa-
tion between OBI and severe liver diseases, particularly 
in patients with HCV infection. This suggests that OBI 
may favor or accelerate the progression toward cirrhosis 
in these individuals (31). Mild necroinflammation can be 
revealed many years after the resolution of acute hepa-
titis Infections. This may explain how a persistent, yet 
suppressed, viral infection may have pathogenic activity. 
As they have similar transmission modes, HBV and HCV 
co-infection are common clinical presentations. Because 
prevention is the first line of defense against viral hepa-
titis infection and is much more cost-effective than treat-
ment, prevention should be the main goal of current ef-
forts to break the vicious cycle of the infection.
In Egypt, HBV vaccination of newborns has been avail-
able for populations at high risk of HBV infection since 
1992. However, neither children nor young adults were 
provided with “catch-up vaccinations” (32). The govern-
ment should provide more support for the vaccine, es-
pecially for the vaccination of high-risk groups, such as 
HD patients and medical staff, as the cost of treatment is 
much higher than the cost of vaccination. The prevalence 
of OBI among high-risk groups, such as HD patients, can 
only be definitively determined from a large, national ep-
idemiological study. As there is no such national sample 
survey in Egypt, our study provides a useful compromise. 
This study demonstrated that greater attention on the 
part of government health authorities is still needed for 
appropriate prevention of viral hepatitis. Our study find-
ings highlight the significance of continuing prevention 
of HBV through vaccination campaigns as well as the de-
velopment of an integrated strategy for primary preven-
tion that focuses on identification of the risk factors that 
may, if addressed, help curtail the spread of HBV infec-
tions in developing countries. 
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